The expression of a foreign antigen is the likely reason for a noticeable reduction in tumor burden for B14.3 HER2 cells when compared to the parental HER2-negative cells (S1 Fig) and may contribute to the variability in tumour burden within all treatment groups. Here, ERBB2 is linked to neoplasm.